About Choksi Laboratories Limited
Data last updated: 28 September 2026
Choksi Laboratories Limited is a public limited company based in Indore, Madhya Pradesh, India. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 29 January 1993, the company has been in operation for over 33 years.
Registered with ROC Gwalior under CIN L85195MP1993PLC007471. Listed on BSE: 526546.
Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹6.97 Cr. Formerly known as Choksi Analytical Services Limited. It is led by directors including Himika Choksi and Raghmendra Singh.
Last AGM: 16 September 2025. Financial statements filed for year ended 31 March 2025. Office: 1 Near Tulsiyana Industrial Park, Indore, Madhya Pradesh.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹46.01 Cr, a growth of 10.12% compared to the previous year. The net worth stands at ₹25.58 Cr (up 8.34% YoY). Total assets are valued at ₹61.84 Cr (up 13.16% YoY).
The company has a workforce of approximately 318 employees as per the latest available data.
The company is associated with 1 brand - Choksi Laboratories. As per MCA filings, the company has open charges of ₹34.16 Cr and satisfied charges of ₹49.89 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website choksilab.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressSurvey No 9/1 Near Tulsiyana Industrial Park Gram Kum, Erdi, Indore, Madhya Pradesh, India – 452010
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Choksi Laboratories Limited
Choksi Laboratories Limited operates one associated brand: Choksi Laboratories. These brands represent Choksi Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Laboratory services for pharmaceutical and food analysis are provided. | choksilab.com |
Business Activity of Choksi Laboratories Limited
Choksi Laboratories Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including architecture, engineering activities, technical testing and analysis activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M4 | Architecture, engineering activities, technical testing and analysis activities | Locked |
Business activity turnover details for Choksi Laboratories Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Choksi Laboratories Limited
Choksi Laboratories Limited is audited by Prateek Jain & Co for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Prateek Jain & Co | Locked | Locked | Locked |
Complete auditor history for Choksi Laboratories Limited
Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Choksi Laboratories Limited
Choksi Laboratories Limited is currently managed by 8 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Himika Choksi
Also directs:
Corequal Systems Llp
|
Whole-Time Director | 01 Mar 2017 | 9 Years 6 Months | Current |
| Raghmendra Singh | Director | 13 Aug 2022 | 4 Years 1 Months | Current |
| Vyangesh Choksi | Whole-Time Director | 01 Aug 2009 | 17 Years 1 Months | Current |
|
Sunil Kumar Choksi
Also directs:
Corequal Systems Llp
|
Managing Director | 01 Sep 2008 | 18 Years 0 Months | Current |
| Stela Choksi | Whole-Time Director | 01 Apr 2011 | 15 Years 5 Months | Current |
| Prachi Mantri | Director | 03 Feb 2024 | 2 Years 7 Months | Current |
Financials of Choksi Laboratories Limited FY 2025-26 filings available
Choksi Laboratories Limited reported revenue of ₹46.01 Cr (up 10.12% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 46.01 | 41.78 | 36.70 | 34.44 | 30.04 | 25.69 | 28.16 |
| Revenue growth | +11.0% | +15.3% | +6.8% | +17.0% | -2.0% | -22.3% | +4.8% |
| EBITDA | 12.18 | 11.30 | 10.27 | 9.70 | 8.90 | 4.12 | 0.41 |
| EBITDA margin | +26.5% | +27.1% | +28.0% | +28.2% | +29.6% | +16.0% | +1.5% |
| Profit before tax | 3.20 | 2.15 | 1.66 | 3.72 | 0.36 | (2.81) | (5.71) |
| Net profit | 1.04 | 1.52 | 1.11 | 1.64 | 0.20 | (2.62) | (0.75) |
| Net profit margin | +2.3% | +3.6% | +3.0% | +4.8% | +0.7% | -10.2% | -2.7% |
| EPS (₹) | 2.82 | 2.19 | 1.59 | 4.61 | 0.30 | (3.74) | (5.58) |
| Balance sheet | |||||||
| Total assets | 61.84 | 54.65 | 54.90 | 55.05 | 56.58 | 57.96 | 54.82 |
| Net worth | 25.58 | 23.61 | 22.22 | 21.11 | 17.91 | 17.75 | 20.23 |
| Total debt | 34.17 | 29.15 | 30.87 | 32.41 | 37.29 | 39.15 | 31.64 |
| Cash & bank | 0.21 | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 |
| Net working capital | 8.80 | 5.64 | 7.52 | 8.64 | 6.18 | 4.61 | 6.36 |
| Cash flow | |||||||
| Cash from operations | 7.86 | 11.78 | 11.55 | 8.25 | 7.88 | 5.90 | 2.87 |
| Cash from investing | (7.07) | (7.61) | (6.65) | (0.71) | (2.71) | (7.65) | (13.76) |
| Cash from financing | (1.20) | (4.22) | (4.58) | (7.61) | (5.07) | 1.63 | 11.09 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06 | 12.82 | 10.82 | 11.12 | 11.24 | 11.40 | 10.38 | 9.26 |
| Revenue growth (YoY) | +7.3% | +12.5% | +4.2% | +20.1% | +4.7% | +2.5% | +18.1% | +16.5% |
| Other income | 0.02 | 0.06 | 0.89 | 0.01 | 0.00 | 0.04 | 0.01 | 0.01 |
| Total expenses | 8.78 | 9.18 | 8.17 | 8.19 | 8.34 | 7.90 | 7.84 | 6.90 |
| EBITDA | 3.28 | 3.64 | 2.65 | 2.93 | 2.90 | 3.50 | 2.54 | 2.36 |
| EBITDA margin | +27.2% | +28.4% | +24.5% | +26.3% | +25.8% | +30.7% | +24.5% | +25.5% |
| Depreciation | 1.97 | 1.89 | 1.83 | 1.69 | 1.68 | 1.70 | 1.68 | 1.61 |
| Interest | 0.73 | 0.71 | 0.81 | 0.69 | 0.60 | 0.58 | 0.69 | 0.66 |
| Profit before tax | 0.60 | 1.10 | 0.90 | 0.56 | 0.62 | 1.26 | 0.18 | 0.10 |
| Tax | 0.02 | 0.07 | 0.59 | 0.32 | 0.24 | 0.34 | 0.08 | 0.02 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06 | 12.82 | 10.82 | 11.12 | 11.24 | 11.40 | 10.38 | 9.26 |
| Revenue growth (YoY) | +7.3% | +12.5% | +4.2% | +20.1% | +4.7% | +2.5% | +18.1% | +16.5% |
| Other income | 0.02 | 0.06 | 0.89 | 0.01 | 0.00 | 0.04 | 0.01 | 0.01 |
| Total expenses | 8.78 | 9.18 | 8.17 | 8.19 | 8.34 | 7.90 | 7.84 | 6.90 |
| EBITDA | 3.28 | 3.64 | 2.65 | 2.93 | 2.90 | 3.50 | 2.54 | 2.36 |
| EBITDA margin | +27.2% | +28.4% | +24.5% | +26.3% | +25.8% | +30.7% | +24.5% | +25.5% |
| Depreciation | 1.97 | 1.89 | 1.83 | 1.69 | 1.68 | 1.70 | 1.68 | 1.61 |
| Interest | 0.73 | 0.71 | 0.81 | 0.69 | 0.60 | 0.58 | 0.69 | 0.66 |
| Profit before tax | 0.60 | 1.10 | 0.90 | 0.56 | 0.62 | 1.26 | 0.18 | 0.10 |
| Tax | 0.02 | 0.07 | 0.59 | 0.32 | 0.24 | 0.34 | 0.08 | 0.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 46.01 | 41.78 | 36.70 | 34.44 | 30.04 | 25.69 | 28.16 |
| Revenue growth | +11.0% | +15.3% | +6.8% | +17.0% | -2.0% | -22.3% | +4.8% |
| Other income | 0.97 | 0.07 | 0.16 | 3.04 | 0.12 | 0.49 | 0.33 |
| Total expenses | 33.83 | 30.48 | 26.43 | 24.74 | 21.14 | 21.57 | 27.75 |
| Employee cost | 16.62 | 15.22 | 13.03 | 12.00 | 11.04 | 10.78 | 11.70 |
| EBITDA | 12.18 | 11.30 | 10.27 | 9.70 | 8.90 | 4.12 | 0.41 |
| EBITDA margin | +26.5% | +27.1% | +28.0% | +28.2% | +29.6% | +16.0% | +1.5% |
| Depreciation | 7.09 | 6.50 | 5.71 | 5.50 | 5.43 | 4.60 | 4.56 |
| Interest | 2.86 | 2.72 | 3.06 | 3.52 | 3.23 | 2.82 | 1.89 |
| Profit before tax | 3.20 | 2.15 | 1.66 | 3.72 | 0.36 | (2.81) | (5.71) |
| Tax | 1.23 | 0.63 | 0.55 | 0.51 | 0.16 | (0.20) | (1.83) |
| Net profit | 1.04 | 1.52 | 1.11 | 1.64 | 0.20 | (2.62) | (0.75) |
| Net profit margin | +2.3% | +3.6% | +3.0% | +4.8% | +0.7% | -10.2% | -2.7% |
| EPS (₹) | 2.82 | 2.19 | 1.59 | 4.61 | 0.30 | (3.74) | (5.58) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| Reserves & surplus | 18.61 | 16.64 | 15.25 | 14.14 | 10.94 | 10.78 | 13.26 |
| Shareholders' funds (net worth) | 25.58 | 23.61 | 22.22 | 21.11 | 17.91 | 17.75 | 20.23 |
| Secured loans | 27.83 | 28.07 | 29.27 | 30.35 | 33.77 | 35.14 | 30.36 |
| Unsecured loans | 6.34 | 1.08 | 1.60 | 2.06 | 3.52 | 4.01 | 1.28 |
| Total debt | 34.17 | 29.15 | 30.87 | 32.41 | 37.29 | 39.15 | 31.64 |
| Total liabilities | 61.84 | 54.65 | 54.90 | 55.05 | 56.58 | 57.96 | 54.82 |
| Assets | |||||||
| Gross block | 94.13 | 84.72 | 74.31 | 70.94 | 68.71 | 67.56 | 45.94 |
| Net block | 51.55 | 47.62 | 43.44 | 44.83 | 46.56 | 50.32 | 33.08 |
| Capital work in progress | 0.40 | 0.00 | 2.99 | 0.31 | 1.67 | 0.50 | 13.06 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.24 | 0.56 | 0.36 | 0.21 | 0.25 | 0.11 | 0.18 |
| Sundry debtors | 14.73 | 11.27 | 10.39 | 10.65 | 10.29 | 8.16 | 6.99 |
| Cash & bank balances | 0.21 | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 |
| Loans & advances | 3.70 | 3.88 | 3.16 | 2.75 | 3.06 | 4.45 | 8.95 |
| Total current assets | 18.88 | 16.32 | 14.57 | 13.95 | 14.01 | 13.03 | 16.55 |
| Total current liabilities | 10.08 | 10.68 | 7.05 | 5.31 | 7.83 | 8.42 | 10.19 |
| Net working capital | 8.80 | 5.64 | 7.52 | 8.64 | 6.18 | 4.61 | 6.36 |
| Total assets | 61.84 | 54.65 | 54.90 | 55.05 | 56.58 | 57.96 | 54.82 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 | 0.23 |
| Net cash from operating activities | 7.86 | 11.78 | 11.55 | 8.25 | 7.88 | 5.90 | 2.87 |
| Net cash from investing activities | (7.07) | (7.61) | (6.65) | (0.71) | (2.71) | (7.65) | (13.76) |
| Net cash from financing activities | (1.20) | (4.22) | (4.58) | (7.61) | (5.07) | 1.63 | 11.09 |
| Net change in cash | (0.41) | (0.04) | 0.32 | (0.07) | 0.10 | (0.12) | 0.20 |
| Closing cash | 0.21 | 0.61 | 0.66 | 0.34 | 0.41 | 0.31 | 0.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +10.1% | +13.8% | +6.6% | +14.7% | +16.9% | -8.8% | -16.6% |
| EBITDA growth | +7.8% | +10.0% | +5.9% | +9.0% | +116.0% | +904.9% | -94.4% |
| PBT growth | +48.8% | +29.5% | -55.4% | +933.3% | +9998.0% | +50.8% | - |
| Net income growth | -31.6% | +36.9% | -32.3% | +720.0% | +9998.0% | -249.3% | - |
| Revenue CAGR (3Y) | +10.1% | +11.6% | +12.6% | +6.9% | -3.8% | -5.5% | -0.7% |
| EBITDA CAGR (3Y) | +7.9% | +8.3% | +35.6% | +187.1% | +7.0% | -13.4% | -55.9% |
| Profitability & leverage | |||||||
| Net income margin | +4.3% | +3.6% | +3.0% | +9.3% | +0.7% | -10.2% | -13.8% |
| Return on capital employed | +9.1% | +8.9% | +8.6% | +8.9% | +6.3% | +0.0% | -1.4% |
| Return on net worth | +4.2% | +6.6% | +5.1% | +8.4% | +1.2% | -13.7% | -3.4% |
| Debt / equity | 1.29 | 1.31 | 1.46 | 1.79 | 2.14 | 1.86 | 1.10 |
| Long-term debt / equity | 0.75 | 0.76 | 1.02 | 1.45 | 1.79 | 1.59 | 0.95 |
| Interest cover | 56.19 | 56.67 | 67.11 | 83.81 | 93.08 | -587.50 | -45.54 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.51 | 0.53 | 0.51 | 0.49 | 0.44 | 0.45 | 0.62 |
| Inventory turnover | 115.03 | 90.83 | 128.77 | 149.74 | 166.89 | 177.17 | 95.46 |
| Debtors turnover | 3.54 | 3.86 | 3.49 | 3.29 | 3.26 | 3.39 | 3.57 |
| EPS (₹) | 2.82 | 2.19 | 1.59 | 4.61 | 0.30 | (3.74) | (5.58) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 36.72 | 33.89 | 31.89 | 30.31 | 25.70 | 25.48 | 29.03 |
Shareholding Pattern of Choksi Laboratories Limited
As per the shareholding pattern for the quarter ended Mar 2026, promoters hold 31.50%, foreign institutional investors hold 6.00%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 62.50% of Choksi Laboratories Limited.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 31.50% | 31.50% | 31.50% | 31.50% |
| Public | 68.50% | 68.50% | 68.50% | 68.50% |
Charges & Borrowings of Choksi Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 May 2026 | Hdfc Bank Limited | ₹18.49 Lakh | Open |
| 31 May 2025 | Hdfc Bank Limited | ₹12.5 Lakh | Open |
| 23 Jan 2025 | State Bank of India | ₹6.75 Cr | Open |
| 21 May 2024 | Hdfc Bank Limited | ₹50 Lakh | Open |
| 10 Oct 2023 | State Bank of India | ₹68 Lakh | Open |
Total charge records: 39 View all charges
Employees and EPFO Compliance at Choksi Laboratories Limited
Choksi Laboratories Limited has a workforce of 318 employees as of Mar 31, 2024.
Employee and EPFO history for Choksi Laboratories Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Choksi Laboratories Limited
GST registrations and filing compliance for Choksi Laboratories Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Choksi Laboratories Limited
Credit ratings, litigation, and regulatory alerts for Choksi Laboratories Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Choksi Laboratories Limited
MSME payment history for Choksi Laboratories Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Choksi Laboratories Limited
Corporate group structure for Choksi Laboratories Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Choksi Laboratories Limited
MCA filings and documents for Choksi Laboratories Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Choksi Laboratories Limited
Recent News on Choksi Laboratories Limited
Frequently Asked Questions about Choksi Laboratories Limited
Choksi Laboratories Limited is an active public limited company in the pharma sector based in Indore, Madhya Pradesh, India. It was incorporated on 29 January 1993 (33+ years old) and is registered under CIN L85195MP1993PLC007471. Listed on BSE: 526546. The company has 318 employees.
Choksi Laboratories Limited reported revenue of ₹46.01 Cr for FY 2025-26 (up 10.12% YoY) based on standalone financials.
The current directors of Choksi Laboratories Limited are:
- Himika Choksi - Whole-Time Director
- Raghmendra Singh - Director
- Vyangesh Choksi - Whole-Time Director
- Sunil Kumar Choksi - Managing Director
- Stela Choksi - Whole-Time Director
- Prachi Mantri - Director
- Abha Shastri - Director
- Ritik Pavecha - Director
The primary industry of Choksi Laboratories Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Yes. Choksi Laboratories Limited is listed on BSE with code 526546.
Choksi Laboratories Limited can be reached at the registered office: Survey No 91 Near Tulsiyana Industrial Park Gram Kum, Erdi, Indore, Madhya Pradesh, India – 452010, or through the website choksilab.com.